We found that 26.6% of MS patients treated with IFN-β1a without preexisting autoimmunity had anti-TPO, indicating that thyroid autoimmunity occurs more frequently in MS patients treated with IFN-β1a than untreated MS patients and healthy controls. Here, TPO is linked to myeloid sarcoma.